Budget impact of upadacitinib in patients with moderate to severe rheumatoid arthritis in Argentina.

ABSTRACT:

Objectives.

To analyze the budget impact of upadacitinib (UPA) 15 mg + methotrexate (MTX) for the treatment of moderate-to-severe rheumatoid arthritis (RA) in patients with an inadequate response to conventional disease-modifying antirheumatic drugs (cDMARD-IR) from the perspective of social security and the private health sector in Argentina.

Materials and methods.

A budget impact analysis model was developed for a hypothetical cohort of 100,000 adults with health insurance coverage who were diagnosed with RA over a 5-year time horizon. The model parameters were obtained through literature review and validated by local experts. The costs are expressed in 2024 US dollars (USD).

Results.

The introduction of UPA 15 mg + MTX for the treatment of moderate-to-severe RA and

SUBMITTER: Espinola N 

PROVIDER: S-EPMC11300694 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature